Zaltrap® (aflibercept): Information on the risk of osteonecrosis of the jaw

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Date: 14 December 2016

 

Description:

Cases of osteonecrosis of the jaw (ONJ) have been reported in cancer patients who have been treated with Zaltrap® (aflibercept). Patients who have also previously or concomitantly received an intravenous bisphosphonate may be at particular risk. Avoid invasive dental procedures, where possible, in patients being treated with Zaltrap® who have previously received, or are currently receiving, an intravenous bisphosphonate. During treatment, advise patients to: maintain good oral hygiene; receive routine dental check-ups; and to report any oral symptoms such as dental mobility, pain, or swelling. Please refer to the Direct Healthcare Professional Communication (DHPC) issued by Sanofi-Aventis (Malaysia) Sdn. Bhd. for further information.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA